Back to search results

Comparing Radical and Precision Prostatectomy for Prostate Cancer

This study compares two surgical approaches for low- and intermediate-risk prostate cancer: Radical Prostatectomy (RP) and Precision Prostatectomy (PP). RP removes the entire prostate and surrounding tissue. PP is similar but aims to protect nerves important for sexual health and bladder control. Researchers want to see if PP can lead to better sexual health and continence outcomes while still effectively treating cancer. You may be able to join if you have prostate cancer, are having surgery at Henry Ford Health, and meet specific criteria like a PSA (Prostate-Specific Antigen) of 20 ng/mL or less and certain biopsy results. The study will measure sexual health at 3 and 12 months after surgery, and social continence at 12 months.

Study design
This interventional study plans to enroll 160 men to compare two surgical procedures. It is not specified if participants will be randomly assigned to a procedure.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for sexual health at 3 and 12 months post-surgery, and for social continence at 12 months post-surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07348367

A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.

Recruiting
NAAll AgesInterventionalTreatment
Henry Ford Health System
~160 participants
Updated 2026-01-16 on ClinicalTrials.gov
What's tested:Radical ProstatectomyPrecision Prostatectomy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sexual Health
Measured over Before surgery, 3 months post-surgery, 12 months post-surgery
+1 more outcome measured

Conditions

Prostatectomy

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Michigan1

Who to contact

Firas Abdollah, MD, FEBU
[email protected]
313-673-7463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Prostate cancer patients receiving treatment at Henry Ford Health from the investigator or co-investigator who opt for surgery.
Prostate-specific antigen (PSA) ≤20 ng/mL
Clinical stage ≤cT2
Dominant unilateral lesion with Gleason ≤4+3 on biopsy
No Gleason ≥4 contralaterally
Preoperative SHIM score ≥17 (with or without phosphodiesterase-5 inhibitor use)

Exclusion

• Androgen deprivation therapy within 6 months.
Nodal positive disease
Metastatic disease
Prior prostate cancer therapy (e.g., radiation, HIFU).
Significant comorbidities precluding surgery or life expectancy \<5 years as defined by the Prostate Cancer Comorbidity Index \[5\].
Any previous cancer diagnosis.

What this trial measures

  • Sexual HealthBefore surgery, 3 months post-surgery, 12 months post-surgery

    Patients' sexual health and function is measured by the Sexual Health Inventory for Men (SHIM). A SHIM score \> 16 is considered sexually healthy.

  • Social Continence12 months post-surgery.

    Continence is determined by the number of pads used per day by patients. Social continence is defined as \< 2 pads per day.